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Abstract
Background: Schizophrenia is a severe, chronic, and costly illness that adversely impacts patients'
lives and health care payer budgets. Cost comparisons of treatment regimens are, therefore,
important to health care payers and researchers. Pre-Post analyses ("mirror-image"), where
outcomes prior to a medication switch are compared to outcomes post-switch, are commonly
used in such research. However, medication changes often occur during a costly crisis event.
Patients may relapse, be hospitalized, have a medication change, and then spend a period of time
with intense use of costly resources (post-medication switch). While many advantages and
disadvantages of Pre-Post methodology have been discussed, issues regarding the attributability of
costs incurred around the time of medication switching have not been fully investigated.
Methods:  Medical resource use data, including medications and acute-care services
(hospitalizations, partial hospitalizations, emergency department) were collected for patients with
schizophrenia who switched antipsychotics (n = 105) during a 1-year randomized, naturalistic,
antipsychotic cost-effectiveness schizophrenia trial. Within-patient changes in total costs per day
were computed during the pre- and post-medication change periods. In addition to the standard
Pre-Post analysis comparing costs pre- and post-medication change, we investigated the sensitivity
of results to varying assumptions regarding the attributability of acute care service costs occurring
just after a medication switch that were likely due to initial medication failure.
Results:  Fifty-six percent of all costs incurred during the first week on the newly initiated
antipsychotic were likely due to treatment failure with the previous antipsychotic. Standard
analyses suggested an average increase in cost-per-day for each patient of $2.40 after switching
medications. However, sensitivity analyses removing costs incurred post-switch that were
potentially due to the failure of the initial medication suggested decreases in costs in the range of
$4.77 to $9.69 per day post-switch.
Conclusion: Pre-Post cost analyses are sensitive to the approach used to handle acute-service
costs occurring just after a medication change. Given the importance of quality economic research
on the cost of switching treatments, thorough sensitivity analyses should be performed to identify
the impact of crisis events around the time of medication change.
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Background
Pre-Post (or "mirror-image") designs are studies where
one compares outcomes prior to and after some event –
such as a medication change. The focus here is on pre-post
comparisons of economic outcomes from patients switch-
ing medication treatment for schizophrenia. In long term
treatment for schizophrenia, treatment switching is com-
mon, and there is a great need for information on treat-
ment options for patients requiring a medication switch
[1-3]. Due to the large impact of schizophrenia care on
health care payer budgets, the comparison of treatments
on economic outcomes has been the focus of much
research [4,5]. Understanding if the costs of care decrease
upon a change to a particular medication is often a
research question of interest that is assessed using pre-post
analyses. Hudson and colleagues [6] reviewed 10 eco-
nomic outcome studies of antipsychotic medications
using various pre-post designs and reported mixed results.
More recently, pre-post assessments of costs were reported
for patients with schizophrenia switching to amisulpride
[7], switching between risperidone and olanzapine [8,9]
and switching from typicals to atypicals [10].
Health-care decision makers often utilize observational
data to assess economic outcomes [11,12]. In comparison
to clinical trials, observational research provides broader
generalizability due to its utilization of cost and medical
resource data which is both real-world and less influenced
by protocol-required visits, compliance, and other proce-
dures [11,13]. However, observational data is subject to
selection bias that complicates comparisons between
nonrandomized groups of patients [14]. One advantage
of Pre-Post analyses is that they allow for 'within-patient
analyses' (each patient is their own control) – thus avoid-
ing the need to adjust for selection bias that complicates
comparisons between (nonrandomized) groups of
patients in naturalistic research.
Pre-post analyses have several important disadvantages
that have been well described in the literature [15]. These
include regression to the mean, time period bias, lack of a
control group, and asymmetrical treatment durations. In
usual clinical practice settings for the treatment of schizo-
phrenia and other episodic disease states, treatment
changes are typically made during a time of symptom
exacerbation or a relapse which may require acute care
services. Thus, on average, one might expect symptoms to
be ameliorated and costs to decrease from that time point.
Pre-post analyses compare outcomes that occurred at dif-
ferent times on the same patient under different treatment
conditions. Inferring that differential outcomes are due to
treatment differences requires one, among other things, to
assume no period/time effect, which is especially prob-
lematic in the study of episodic disease states such as
schizophrenia.
Pre-post analyses are not, in general, suited to address
broader questions of interest requiring multiple compari-
son groups. For instance, in the treatment of schizophre-
nia one might be interested in evaluating the multiple
treatment options at the point of medication change,
including switching to one of several medications or
changing the dose of the current medication. One option
in such instances is to utilize randomization to several
treatment options for comparison at the time point where
patients were in need of a medication change – as was
done in the Clinical Antipsychotic Trials of Intervention
Effectiveness (CATIE) [1,16,17]. In naturalistic settings,
the duration of each (pre- and post-) treatment varies –
thus raising challenges when comparing outcomes based
on differing treatment durations. While one can just
assess a set period of time, pre- and post-switch, the effect
of a drug may differ in the first few weeks of treatment rel-
ative to a later period of treatment.
Another limitation of pre-post designs for cost compari-
sons that has received less attention is the issue of costs
incurred while on treatment B (the medication switched
to) which may have been due to the failure of treatment A
(the initial medication). For instance, while there are
many reasons for switching treatment, the most common
is lack of efficacy [18], which includes patients who
relapse – leading to crisis management such as a hospital-
ization where treatment A is discontinued and treatment
B is first initiated in the hospital. Costs for the manage-
ment of this relapse may continue for some time after dis-
continuation of treatment A. While this issue has been
raised [15], this is especially important for economic anal-
yses because hospitalizations and the cost of relapse rep-
resent the largest portion of health care costs for patients
with schizophrenia [19-22].
Our objective in this paper is to highlight the issue of over-
lapping or carry-over costs from a failed prior treatment
onto the next treatment in pre-post medication switch
analyses. We accomplish this by examining the sensitivity
of pre-post analyses of changes in costs of care to various
assumptions regarding the attributability of acute-care
service costs occurring immediately after a medication
switch. Data from a naturalistic schizophrenia study is uti-
lized for the analysis.
Methods
Study Design
Data for this post-hoc analysis came from a cost-effective-
ness study of first-line treatment with atypical and con-
ventional antipsychotics over a 1-year period [23,24]. This
randomized, naturalistic, open-label trial was conducted
from May 1998 through September 2001 at 21 sites in 15
states in the United States. This study used broad eligibil-
ity criteria. Patients aged 18 years or older with a DSM-IVCost Effectiveness and Resource Allocation 2009, 7:11 http://www.resource-allocation.com/content/7/1/11
Page 3 of 7
(page number not for citation purposes)
diagnosis of schizophrenia, schizoaffective, or schizo-
phreniform disorder were included, provided they scored
≥ 18 on the Brief Psychiatric Rating Scale (BPRS) [25]. No
patient was excluded because of comorbid substance
abuse disorder or other psychiatric or medical comorbid-
ities. Patients were randomly allocated to a first-line treat-
ment group: 1 of 2 atypical antipsychotics (n = 450) or a
conventional first-generation antipsychotic of each physi-
cian's choosing (n = 214). Barring clinically significant
adverse events, patients remained on their initial medica-
tions for at least 8 weeks, after which they could change
medications if a switch was clinically warranted. Medica-
tions could also be discontinued, or their doses altered, at
each physician's discretion.
Definitions and Measures
Patients were defined as having switched medications if
they discontinued the medication to which they were ini-
tially randomized and then initiated therapy with a differ-
ent antipsychotic within 14 days. Acute-care services were
defined as hospitalizations, partial hospitalizations, and
visits to emergency departments (EDs). Data on each
patient's use of such services were systematically
abstracted from medical records, patient self-reports, and
the study sites' administrative databases. Cost estimates
applied to each unit of resource use have been previously
described in detail [24]. In brief, Medicare public data
were used as cost benchmarks for units of specific services
and applied to the collected resource use data to obtain
costs of care for each patient. Medication costs were based
on 2001 average wholesale prices, discounted 15% to
reflect real-world costs [24].
Analysis Methods
To examine the impact of carry-over (overlapping) costs,
we analyzed switching data using 4 different approaches –
each making different assumptions regarding the attribut-
ability of costs and timing of incurred costs potentially
due to the initial (pre) treatment. To standardize the 2
evaluation periods to a common duration, we chose to
evaluate the last 60 days on the Pre-treatment and the 1st
60 days on the Post-treatment. The goal was to use a short
enough duration to avoid deletion of patients from the
analysis (or imputation of missing data) who only had
short durations in the study pre- and/or post-switch and
long enough to provide a more stable assessment of costs
while on the medication. As secondary analyses, we uti-
lized a 30-day window. Costs in the post-period were
computed regardless of additional subsequent switches in
medications. Costs are presented on an average daily basis
to allow for comparisons across methods on a standard
time scale. The 4 analysis approaches were:
Standard Pre-Post
Costs incurred during the 60 days leading up to the last
day on the initial medication are defined as 'Pre' period
costs. Costs incurred starting from the day after the initial
medication was discontinued for the next 60 days are
defined as 'Post' period costs.
Remove Overlapping Acute Crisis Costs from Post Period
Costs of acute care services that began while on the initial
medication, but continued into the 'Post' medication
period, were excluded from the analysis. Otherwise, calcu-
lations were the same as for the Standard Pre-Post Switch
Analysis.
Exclude first 2 weeks of the Post Period
Calculations follow the Standard Pre-Post Switch analysis
except that the first 14 days of the Post period were
excluded from the calculations. The 2-week cutoff was
selected as most hospitalization durations were less than
14 days, so the impact of hospitalizations beginning in
the 'pre' period would be addressed and since research
suggests that impact of new medication could be observa-
ble by 2 weeks [26-28].
Assign first 2 weeks of Post Costs to Pre Medication
Calculations follow the Standard Pre-Post Switch analysis
except that costs occurring in the first 14 days in the post
period are assigned to the Pre-treatment period.
Paired differences in costs (Pre-Post) were compared sta-
tistically (with a null hypothesis of no change in mean
costs) using both a paired t-test and, due to the skewness
of the cost data, a nonparametric bootstrapping approach.
The bootstrapping approach was utilized as we desired a
nonparametric approach due to the anticipated skewed
cost data and a test for differences in means as opposed to
medians. Means are the appropriate parameter of interest
as health care payers are responsible for the cost of the
entire population, and N-times-the-median may not be
representative of the total costs given skewed distributions
[29,30].
Results
A total of 664 patients were randomized, though 13 never
started on their assigned medication [24]. Of the 651 ana-
lyzable patients, 191 (29.3%) switched antipsychotics at
some point during the 1-year study; 144 patients switched
antipsychotics AND had information in the study from 30
days pre- to 30 days post-switch available for analysis; and
105 patients switched antipsychotics and had informa-
tion from 60 days pre- and post-switch available for anal-
ysis. Thus, analyses here are based on 105 patients.
Analysis with the 30-day requirement (n = 144) provided
similar results. Of the 460 patients who did not switch
antipsychotics during the study, 31.7% were early discon-
tinuers and did not complete 1 year on study. It is antici-
pated that some of these patients may have changed
medications outside of the clinical study. Thus, actual
rates of switching is anticipated to be greater than 29.3%,Cost Effectiveness and Resource Allocation 2009, 7:11 http://www.resource-allocation.com/content/7/1/11
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but data on these potential switching patients was not
available.
Table 1 summarizes the patient characteristics at study
enrollment. Patient characteristics of the switchers were
relatively similar to the nonswitchers except for having a
greater proportion of females, lower rates of substance
abuse, and prior-year hospitalizations.
Figure 1 summarizes the average total cost per patient per
day relative to the time of the medication switch. Costs
clearly increased on the day of switch and remained high
through the first week after switch. Costs from acute crisis
treatment such as hospitalizations, partial hospitaliza-
tions, and emergency room visits that started while on the
initial medication and continued after the medication
switch made up 58 percent of the costs during the first
week post-switch and 26% of the costs in the second week
post-switch. While one cannot be completely sure of
attributability in such cases, given the timing of the hospi-
tal admissions (or initiation of partial hospitalization
treatment) such costs were determined to be more appro-
priately linked to failure of the first treatment rather than
the lack of effectiveness of the next treatment.
Table 1: Patient Characteristics at Study Enrollment
Analyzed Switchers a All Switchers Non-Switchers
N 105 191 460
Male, % 49.5 b 54.5 c 66.7 b, c
Age, mean (SD) 43.8 (13.2) 42.8 (12.5) 42.9 (11.9)
Age of onset, mean (SD) 22.5 (8.5) 22.1 (8.8) 22.3 (9.8)
Unemployed, (%) 82.9 81.2 81.1
Race, (%)
Caucasian 58.1 56.0 53.7
African descent 34.3 33.0 33.9
Other 7.6 11.0 12.4
Diagnosis, (%)
Schizophrenia 65.7 63.4 66.1
Schizoaffective 27.6 28.3 25.9
Schizophreniform 6.7 8.4 8.0
Comorbidities (%)
MDD 14.3 14.7 13.9
Anxiety 3.8 2.6 6.3
Substance Abuse 20.2b 27.4 33.7 b
Baseline PANSS total, mean (SD) 84.6 (19.3) 84.5 (18.8) 87.8 (20.3)
Hospitalization in year prior to enrollment 22.1b 27.1 32.3b
Abbreviations: PANSS, positive and negative syndrome scale; MDD, Major Depressive Disorder
aSwitchers with 60 days pre-switch and 60 days post-switch information available
bp-value < .05 for comparison between analyzed switchers and nonswitchers
cp-value < .05 for comparison between all switchers and nonswitchersCost Effectiveness and Resource Allocation 2009, 7:11 http://www.resource-allocation.com/content/7/1/11
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Figure 2 summarizes the 60-day pre and post costs using
each of the 4 methods. Standard Pre-Post analyses suggest
an average increase in cost per day for each patient of
$2.40 after switching medications. However, the other
analyses suggested a decrease in the range of $4.77 –
$9.69 per day post-switch. The $4.77 decrease was esti-
mated when the first 14 days in the post period was
excluded and the $9.69 decrease was estimated when the
entire first 14 days in the post period was considered as
part of the pre period. The difference in the estimated
change in daily costs, pre to post, varied by over $12 per
day.
None of the changes in costs were statistically significant
from zero, and confidence intervals on the differences in
pre-post cost changes for the 4 approaches are large and
overlapping. For example, the 95% two-sided confidence
interval for the standard approach was (-$12.12, $18.69)
and for assigning the first 14 days of post costs to the pre
period was (-$24.55, $5.71). Due to the high variability in
total costs of care, such studies must be fairly large in
order to have enough power for relevant cost compari-
sons. However, the focus here was not on establishing
whether a change in costs occurred, but to compare the
methodologies.
Discussion
The current analyses have demonstrated that assumptions
about costs potentially attributable to failure of the first
medication can have a directional impact on results when
assessing the economic impact of changing medications
using a pre-post analysis. The difference in estimated
changes in daily costs in this study varied by over $12 per
day across the methods utilized (between -$9.69 and
+$2.40). Acute care service costs, which is the largest cost
component in the treatment of schizophrenia, is often
associated with relapse and with changes in medications,
and thus must be considered carefully. Given the variation
in results depending upon the attribution of crisis care
costs around the time of switch, sensitivity analyses are
critical to proper understanding of such data.
Caution regarding the analysis of costs occurring around
the time of switch should not be limited to pre-post
designs. For instance, in clinical trials patients are typically
discontinued at the point at which they have a medication
change. This potentially ignores a substantial amount of
the treatment costs which would then occur outside of the
purview of the trial. In practical clinical trials, where
patients are allowed to change medications and remain in
Mean Total Cost Per Day Relative to the Time of Switching  Antipsychotics (N = 105) Figure 1
Mean Total Cost Per Day Relative to the Time of 
Switching Antipsychotics (N = 105). aFor example, the 
'3 wks Prior' column indicates the average daily total cost of 
care for patients during the 15 to 21 days (inclusive) prior to 
the medication switch.
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the study, it is common to conduct an analysis including
only the period of time in which the patient was on the
medication of interest [31]. Once again, this analysis
could be misleading due to missing the potentially large
costs occurring just after discontinuing the medication
that should be owned by the initial medication.
The availability of data from a control group may address
some of the issues associated with pre-post analyses. For
instance, pre- and post-switch data for patients treated
with a comparison medication would allow for additional
methodological approaches to be used. Fu and colleagues
[32] compare the use of a difference-in-differences
approach along with propensity score-based methodol-
ogy in such settings. One may also benefit by considering
a pre-post analysis in comparison to assessing treatment
effects in a crossover design. Without a control group, one
simply has a single arm of a standard 2 × 2 crossover trial.
The availability of a comparator group may also allow the
use of crossover related methods [33].
This study has several limitations. First, the number of
patients switching was relatively small for comparisons of
costs. Replication with a larger sample is needed due to
the high variability in cost data. Next, we were unable to
fully collect the reason for switching, which may indeed
be associated with costs incurred around the time of
switch. Lastly, about one-third of the nonswitchers dis-
continued early from the study. Some proportion of these
patients likely switched medications outside of the pur-
view of the trial, but we were unable to collect post-switch
economic data for these patients. At baseline, these early
discontinuers were more likely to be male; had more
severe symptoms (as measured by the BPRS); and had a
higher rate of prior hospitalization, substance abuse, and
comorbid anxiety as compared to the switchers in this
study. Thus, it is not clear if the results observed here are
generalizable to such patients.
Conclusion
Pre-post cost analyses ("mirror-image") are complicated
by costs incurred post-switch that are likely due to the fail-
ure of the initial treatment. Such costs are not ignorable
and can have substantial impact on the analyses. Sensitiv-
ity analyses should be performed to identify the impact of
such costs.
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